♢♢ Note: I and others entered into a securities transaction with Provectus in March 2017.
Why I'm Long Provectus Pharmaceuticals, Seeking Alpha, September 24, 2013
Why I'm Long Provectus Pharmaceuticals, Seeking Alpha, September 24, 2013
PV-10, a novel oncology compound being developed by Knoxville, Tennessee-based Provectus Pharmaceuticals, Inc. ("Provectus" or the "Company") (OTC:PVCT), exemplifies innovation over incrementalism, meaningful over marginal, productized technology over hypothetical, and changing the world over accepting the status quo, with not an insignificant amount of serendipity over contrivance. In sum, these form the quintessential essence of a paradigm shift in the treatment of cancer.
This is where my investment thesis begins and ends: a novel drug compound with a pristine safety profile, a treatment well tolerated by and easily administered to patients, a readymade product inexpensively produced at scale, and a vast addressable market of unmet need that should be fully and very profitably met over time.Why I Remain Long Provectus Biopharmaceuticals, Connecting the dots, March 28, 2015
My investment thesis is intact. Up until this point FDA regulatory clarity had been lacking and therefore commercial validation was absent despite compelling clinical and business value propositions of Provectus’ Rose Bengal-based investigational oncology and dermatology compounds PV-10 and PH-10, respectively. Company management achieved regulatory clarity. Commercial validation should follow. Thus, I remain long the stock.Reproducibility, the Hallmark of Western Science, Connecting the dots, version 1, June 13, 2015; Connecting the dots, version 2, December 28, 2015 (backdated), MicroCap Review, pp. 91-94, Winter/Spring 2016 and Stock News Now, February 17, 2016 (unattributed, see the blog's Disclosure page on this topic)
When Provectus Biopharmaceuticals Chairman, CEO and co-founder Dr. Craig Dees, PhD talks about his company’s investigational cancer drug PV-10 (made from century’s old Rose Bengal), he points to a history of reproducible therapeutic features, and reproduced preclinical and clinical results by multiple clinicians and researchers in multiple cancer indications. Craig refers to reproducibility as the hallmark of Western science. If a scientist cannot repeat an experiment’s outcome, and if another scientist cannot replicate that result, the veracity of the original work and claims made from it may be questionable.The Risk-Reward of Provectus Biopharmaceuticals: Management, Connecting the dots, July 1, 2015
When I wrote my follow-up investment letter Why I Remain Long Provectus Biopharmaceuticals (March 2015) I did not include a treatment of risk (like I did in my initial letter Why I'm Long Provectus Pharmaceuticals, September 2013). I see our investment's singular risk as the company's management team; more specifically, their ability (or lack thereof) to put Provectus in a position to be monetized at or near a value commensurate with their drug's worth.Provectus Biopharmaceuticals: Advancing a New Front in the War against Cancer, Connecting the dots, July 27, 2015 (backdated), MicroCap Review, pp. 6-8, Summer/Fall 2015, and Stock News Now, October 22, 2015 (unattributed, see the blog's Disclosure page on this topic)
Outsiders to the pharmaceutical industry, three award-winning research scientists from the Department of Energy’s East Tennessee-based Oak Ridge National Laboratory embarked on a path of their own in the 1990s to develop a better way to fight cancer. Hailing from the nationally recognized federal government science and technology facility with a rich history of discovery and innovation, these three technology inventors had been searching for a drug candidate capable of killing cancer cells safely, specifically, completely and quickly. By the end of the decade Drs. Craig Dees, PhD, Timothy Scott, PhD and Eric Wachter, PhD had re-discovered what could turn out to be the ideal cancer killer: Rose Bengal, a molecule with a long and diverse medical history. Ironically the compound had lain around in plain sight of the global pharmaceutical industry for nearly 85 years before Dees et al. began their journey of demonstrating Rose Bengal’s cancer fighting potential.Still Standing, Connecting the dots, October 15, 2015
Rose Bengal (aka Rose Bengal disodium) is a small molecule that laid around in the plain sight of the global biotechnology and pharmaceutical industries for about 85 years before scientists formerly from the U.S. Department of Energy’s Oak Ridge National Laboratory re-discovered it during their search for the ideal cancer killer. Rose Bengal is a water-soluble industrial dye created in Germany in 1882, and a non-biologic whose two-prong approach to fighting cancer (dual mechanisms of action) derives from its physical chemistry.
Rose Bengal’s first recorded medical use was noted in 1914, when it was added to Safranin Victoria Yellow for the treatment of ocular pneumococcal infection. In 1998 Provectus Biopharmaceuticals’ founders Dr. Craig Dees, PhD (Chairman and CEO), Dr. Timothy Scott, PhD (President) and Dr. Eric Wachter, PhD (CTO) identified Rose Bengal as an attractive candidate for preventing the growth and spread of cancer tumors, and possibly even defeating the disease altogether.
